source
- Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launchPfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of its monthly GLP-1 receptor agonist.
- Blackstone bets $1.5B on Pfizer’s obesity drugThe deal will support a sprawling Phase 3 program for a monthly GLP-1 shot Pfizer acquired by winning a bidding war for the drug’s previous owner, Metsera.BioPharma Dive · 1d ago↗ source
- Experts update prostate cancer screening guidelines for menAre you an American man between 50 and 69? You might want to get checked for prostate cancer, ACS says in reversal of previous guidelines.